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The live attenuated yellow fever vaccine 17D (YF-17D) is one of the most effective vac-
cines available, with a 65-yr history of use in >400 million people globally. Despite this 
effi  cacy, there is presently no information about the immunological mechanisms by which 
YF-17D acts. Here, we present data that suggest that YF-17D activates multiple Toll-like 
receptors (TLRs) on dendritic cells (DCs) to elicit a broad spectrum of innate and adaptive 
immune responses. Specifi  cally, YF-17D activates multiple DC subsets via TLRs 2, 7, 8, and 
9 to elicit the proinfl  ammatory cytokines interleukin (IL)-12p40, IL-6, and interferon-𝗂. 
Interestingly, the resulting adaptive immune responses are characterized by a mixed T 
helper cell (Th)1/Th2 cytokine profi  le and antigen-specifi  c CD8+ T cells. Furthermore, 
distinct TLRs appear to differentially control the Th1/Th2 balance; thus, whilst MyD88-
defi  cient mice show a profound impairment of Th1 cytokines, TLR2-defi  cient mice show 
greatly enhanced Th1 and Tc1 responses to YF-17D. Together, these data enhance our 
understanding of the molecular mechanism of action of YF-17D, and highlight the poten-
tial of vaccination strategies that use combinations of different TLR ligands to stimulate 
polyvalent immune responses.
Yellow fever vaccine 17D (YF-17D) is consid-
ered to be one of the most eff  ective  vaccines 
available. During the 65 yr since its development, 
the vaccine has been administered to >400 mil-
lion people world wide with minimal incident 
of severe side eff  ects. YF-17D was developed by 
Max Theiler and associates, who in the 1930’s 
experimentally attenuated the Asibi strain of yel-
low fever virus by >200 serial passages through 
monkeys, mouse embryonic tissue, and chicken 
embryonic tissue cultures (1, 2). Protection is 
achieved in >98% of its recipients for at least 
10 yr, and in many individuals, neutralizing anti-
body titers have been found as many as 35 yr after 
a single vaccination (3, 4). Though neutralizing 
antibody titers are thought to be important in con-
ferring protection against infections with yellow 
fever, YF-17D also has been demonstrated as a 
potent inducer of cytotoxic T cell responses (5).
The effi   cacy of this vaccine has brought it 
to the attention of several researchers who have 
used YF-17D as a viral vector to develop novel 
vaccines against other infectious diseases. For 
example, clinical trials are currently under way 
with chimeric viruses generated by inserting 
genes from other fl  aviviruses such as Japanese 
encephalitis, dengue, and West Nile virus into 
YF-17D. Recombinant forms of YF-17D even 
have been demonstrated as eff  ective vaccines 
against malaria and cancer (6–15).
Despite the vaccine’s effi   cacy in control-
ling yellow fever over the past several decades 
and its promise as a vaccine vector, the cellular 
and molecular mechanisms by which it elicits 
such broad based immunity are unclear. In this 
regard, recent evidence suggests that the in-
nate immune system is a critical determinant 
of the strength and quality of the adaptive 
immune response (16–20). Within the   innate 
immune system, DCs occupy a preeminent 
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position, as they play critical roles in sensing microbial 
stimuli and in initiating and modulating adaptive immune 
responses. Moreover, DCs are equipped to sense microbial 
signatures through pathogen recognition receptors (PRRs), 
such as the Toll-like receptors (TLRs) (17, 21, 22). TLRs 
constitute an evolutionarily conserved family of receptors 
involved in microbe recognition, of which 11 have been 
described in mammals. Diff  erent TLRs appear to recognize 
distinct microbial components. For example, lipopolysac-
charides from Escherichia coli are recognized by TLR4 (23), 
whereas certain lipopeptides, LPS from leptospira (24, 25) 
and Porphyromonas gingivalis (26, 27), and the yeast cell wall 
zymosan (28) are recognized by TLR2. Furthermore, un-
methylated DNA from bacteria and viruses are recognized 
by TLR9 (29–32), single-stranded RNA is recognized by 
TLR7/8 (33–35), and double-stranded RNA is recognized 
by TLR3 (36–38).
Upon recognition of a pathogen via TLRs, the imma-
ture DCs at the site of pathogen entry undergo a maturation 
process during which they exit the site and migrate to the 
T cell–rich areas of the neighboring lymph nodes, where the 
mature DCs present their acquired antigens and stimulate 
  antigen-specifi   c T cells, thus initiating adaptive immunity 
and immune memory.
Interestingly, emerging evidence suggests that the quality 
of the adaptive immune response is partly determined by the 
particular TLR triggered, as well as by the particular subset 
of DC activated (17, 21, 22). Thus, signaling through TLR9 
or 7/8 is known to induce robust IL-12(p70) from mye-
loid DCs (TLR 7/8) (30, 39) and IFN-α production from 
plasmacytoid DCs (40, 41), and cross-presentation of exog-
enous antigens and stimulation of cytotoxic T cells (42, 43). 
In contrast, stimulation of TLR2 by several ligands has been 
shown to stimulate IL-10 and induce Th2 or T regulatory 
responses (44–49).
Given the pivotal role of TLRs and DCs in initiating and 
tuning the adaptive immune response, there is at present 
much interest in exploiting these in the development of novel 
vaccines. However, the converse question of whether some 
of our best, empirically derived vaccines actually work by 
stimulating TLRs is largely unexplored. In this context, we 
sought to determine whether YF-17D triggered the activa-
tion of innate immunity and DCs via TLRs and, if so, what 
eff  ect this had on the quality of the innate and adaptive im-
mune response in the present study. Our data suggest that 
YF-17D activates multiple subsets of DCs by signaling 
through multiple TLRs, including TLR2, 7, 8, and 9, result-
ing in diverse types of adaptive immune responses.
Figure 1.  YF-17D activates human monocyte–derived DCs and plas-
macytoid DCs. Human mDCs were cultured with LPS; YF-17D at an MOI of 
1, 0.1, or 0.01; or they were YF-17D UV or heat inactivated. Cytokines (A) and 
costimulatory molecule expression (B) were measured after 48 h. (A) The 
mean fl  uorescent intensities, are indicated at the top left of each histogram. 
(B, top) In the histograms, the numbers in parentheses represent the mean 
fl  uorescent intensities of the DCs cultured in media alone. (C) PDCs were 
isolated from human blood using BDCA-2 microbeads and culture for 48 h 
before measuring IFN-α. Error bars in A and C represent standard deviation. 
These data are representative of at least four independent experiments.JEM VOL. 203, February 20, 2006  415
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RESULTS
YF-17D activates multiple subsets of human 
and mouse DCs in vitro
To determine whether YF-17D activates DCs, we fi  rst cul-
tured human monocyte-derived DCs [mDCs] with YF-17D 
(Fig. 1). UV irradiated or heated YF-17D was used as a neg-
ative control. These mDCs had a dose-dependent response 
to YF-17D with increasing multiplicities of infection (MOIs) 
of virus leading to greater induction of proinfl  ammatory 
  cytokines, including IL-6, TNF-α, MCP-1, and IP-10 (Fig. 
1 A). YF-17D also induced both IL-12p40 and IL-12p70 
from mDCs, although the amounts induced were lower than 
with LPS, and induction of IL-12p70 was only apparent when 
an additional CD40 ligand signal was provided (in the form 
of a fi  broblast cell line, expressing the CD40 ligand signal), 
consistent with numerous previous studies (e.g., reference 45 
and Fig. S1, available at http://www.jem.org/cgi/content/
full/jem.20051720/DC1). Stimulation of DCs with CD40 
ligand–expressing fi  broblasts alone resulted in little or no IL-
12p70. Furthermore, YF-17D was also an effi   cient inducer 
of the costimulatory molecules CD80 and CD86 (Fig. 1 B). 
Both UV irradiation and heat treatment for 1 h at 56°C of 
YF-17D impaired its ability to stimulate cytokines or induce 
costimulatory molecules on mDCs, although the eff  ects of UV 
irradiation varied with the cytokine being examined. Thus, 
there was only a modest eff  ect of UV irradiation on produc-
tion of IL-10 (Fig. 1) and IL-12p40 (Fig. 2). Therefore, it is 
possible that induction of IL-10 (Fig. 1) and IL-12p40 (Fig. 2) 
by YF-17D is not critically dependent on viral replication, 
and that nonreplicating virions, or non-RNA components 
such as viral proteins, may mediate this.
To evaluate whether YF-17D infects DCs, human 
mDCs were exposed to YF-17D and the intracellular ex-
pression of nonstructural proteins NS4A and NS4B and 
evaluated 48 h after infection. As shown by intracellular 
FACS staining in Fig. S2 (available at http://www.jem.org/
cgi/content/full/jem.20051720/DC1) and consistent with 
similar, recently published observations (50), a signifi  cant 
proportion of DCs contain intracellular NS4A and NS4B. 
Interestingly, enhanced induction of the DC activation 
marker CD86, relative to mock-infected DCs, appears to 
occur in all DCs (Fig. S2). Therefore, although productive 
viral infection induces robust activation of DCs, DCs that 
are not productively infected also appear to be activated, 
Figure 2.  YF-17D activates DCs through multiple TLRs and mul-
tiple T LR adaptor proteins. CD11c+ DCs were isolated from the spleens 
of Flt-3L–injected knockout and age-matched, sex-matched, wild-type 
mice and cultured for 48 h in the presence of TLR agonists and YF. Cell 
culture supernatants were assayed for IL-12p40 and IL-6. (A) MyD88−/− 
mice versus control mice; (B) TIRAP−/− mice versus control mice; 
(C) TLR4−/− mice versus control mice; (D) TLR2−/− mice versus control 
mice; (E) TLR9−/− mice versus control mice; and (F) TLR7−/− mice versus 
control mice. Error bars represent standard deviation. These data are 
  representative of at least four independent experiments. *, indicates 
 statistically  signifi  cant difference (P < 0.005 by paired Student’s t test) 
between wild type (black) and knockout (gray) DCs.416  YF-17D ACTIVATES MULTIPLE TLRS TO STIMULATE POLYVALENT IMMUNITY | Querec et al.
perhaps as a result of viral entry or surface binding to a PRR 
or bystander activation.
Plasmacytoid DCs (pDCs) play a key role in many viral 
infections by producing IFNα, which in turn activates other 
immune cells and induces an antiviral program in cells. To 
determine if YF-17D can activate pDCs, pDCs were iso-
lated from human blood and cultured with the virus. Cell 
culture supernatants were assayed for IFNα. pDCs produced 
high levels of IFNα in response to an MOI of 1 of the virus 
and this cytokine production was greatly inhibited by heat-
ing the virus to 56°C for 1 h (Fig. 1 C). UV irradiation did 
not have as much of an eff  ect on reducing the activation of 
the pDCs.
YF-17D activates DCs through multiple TLRs (TLR2, 7, 8, 
and 9) and multiple TLR adaptors (MyD88 and TIRAP)
Given that YF-17D induced potent activation of DCs, we 
sought to determine the innate immune receptors through 
which YF-17D mediated its eff  ects. For these studies, we 
used mouse DCs based on the inherent advantages in using 
animals defi  cient in specifi  c genes that might provide insights 
into mechanism. Splenic CD11chigh DCs from Flt3 ligand–
treated mice were cultured in vitro with YF-17D, and 6 h 
later, the induction costimulatory molecules were evaluated 
by FACS. As with human DCs, YF-17D induced CD86, 
CD80, and CD40 on splenic DCs (unpublished data). As 
previous studies suggest that several viruses can activate DCs 
via TLRs, we assessed the capacity of YF-17D to activate 
DCs from various TLR-defi  cient mice strains.
MyD88 is an adaptor protein that is associated with all 
TLRs, except TLR3 (36, 51, 52) and that mediates the signal 
transduction from TLRs. Thus, as a fi  rst measure of whether 
any TLRs are involved in the response to YF-17D, CD11c+ 
DCs from MyD88−/− mice or wild-type mice were cultured 
in the presence of live or inactivated virus. As shown in Fig. 
2 A, there was a profound impairment in the induction of 
IL-12p40 and IL-6 by YF-17D in MyD88−/− DCs, relative 
to control DCs from wild-type mice. Furthermore, inactiva-
tion of the virus by UV irradiation or heating to 56°C for 
1 h largely abrogates its ability to induce the cytokine re-
sponse from the wild-type cells. In the case of murine DCs, 
we could not detect signifi  cant numbers of infected cells, 
  either by FACS analysis of the intracellular expression of 
nonstructural proteins NS4A and NS4B, or by a PCR-based 
assay (unpublished data). The reasons for the diff  erences in 
infection between human (Fig. S2) and murine DCs are not 
clear. Despite the apparent lack of productive infection of 
murine DCs, clearly YF-17D does induce robust cytokine 
production from such cells. The likely explanation for this 
might be viral entry or surface binding to a PRR.
In addition to MyD88, at least three other adaptor pro-
teins (TIRAP, TRIF, and TRAM) have been described pre-
viously (51–57). TIRAP appears only to be associated with 
TLR2 and 4 (52, 55), whereas TRIF is only associated with 
TLR3 and 4 (53–56). We cultured splenic CD11chigh DCs 
from TIRAP−/− mice with YF-17D. As shown in Fig. 2 B, 
there was a very signifi  cant diminution of both IL-12p40 and 
IL-6 in response to YF-17D in TIRAP−/−, relative to wild-
type controls. Thus, YF-17D activates DCs through at least 
two diff  erent TLR adaptor proteins, MyD88 and TIRAP.
Next, we determined precisely which TLRs were ac-
tivated by YF-17D. DCs from wild-type mice, TLR2−/−, 
TLR4−/−, TLR7−/−, and TLR9−/− mice were cultured 
in vitro with YF-17D (Fig. 2, C–F). No diff  erence in IL-
12p40 and IL-6 production was observed between the 
TLR4−/− and wild-type cultures. This indicates that TLR4 
does not play a role in the response to YF-17D. In contrast, 
TLR2 does play a role, as TLR2−/− DCs had a greatly im-
paired production of IL-12p40 and IL-6. This is consistent 
with recent reports that certain viruses such as measles (58), 
HCV (59, 60), and LCMV (61) also signal through TLR2. 
Furthermore, TLR7 also appears to be important as DCs from 
TLR7−/− mice display impaired production of IL-12p40 
(Fig. 2 F), consistent with the fact that YF-17D is a single-
stranded RNA virus and previous observations that TLR7 is 
a receptor for single-stranded RNA (33–35, 40). However, 
we could not detect a consistent eff  ect on IL-6 production 
Figure 3.  YF-17D signals through TLR 8. Stably transfected HEK293 
cells expressing human TLR8 and an NFκB-inducible luciferase reporter 
were stimulated with the TLR7/8 agonist 3M-003 or an MOI of 0.1 of YF-
17D. After 1 and 2 d, the cells were lysed an analyzed for luciferase activity.
Figure 4.  YF-17D induces DC activation in vivo. Mice were injected 
with YF-17D, LPS, Pam3Cys, or PBS subcutaneously and the draining 
lymph nodes were collected 24 h later. Costimulatory molecule expression 
on CD11c+ DCs was analyzed by fl  ow cytometry.JEM VOL. 203, February 20, 2006  417
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in TLR 7−/− mice (unpublished data). The   reason for this is 
at present unclear.
Until recently, TLR9 has been shown to respond only to 
particular unmethylated CpG DNA motifs found in certain 
bacteria and viruses (29). Given that YF-17D is an RNA 
  virus, we expected to exclude a role for TLR9 in the vaccine 
response. Surprisingly, TLR9−/− DCs had a clear diminution 
in both IL-12p40 and IL-6, although the induction of these 
cytokines by YF-17D in this strain and its littermate was 
weaker than with the other strains, likely due their mixed 
C57BL/6 × 129 genetic backgrounds. A possible explana-
tion for TLR9 signaling by YF-17D was that there was con-
taminating DNA from the SW480 cells used to grow the 
virus. To address this issue, YF-17D or control CpG DNA 
were pretreated with DNase buff  er and with preincubations 
for 30 min in ice, or at 37°C, or at 37°C in the presence 
of DNase. pDCs were cultured with these various stimuli 
and supernatants were assayed for IFN-α (Fig. S3, available 
at http://www.jem.org/cgi/content/full/jem.20051720/
DC1). Incubation at 37°C had no eff  ect on YF-17D and 
CpG DNA relative to the stimuli on ice (unpublished data). 
DNase treatment substantially reduced cytokine output from 
cultures treated with DNase digested CpG DNA, but had no 
eff  ect on YF-17D, suggesting that the contaminant cellular 
DNA likely did not play a role in the eff  ects of YF-17D on 
DCs. This observation is consistent with the recent fi  nding 
that Newcastle Disease virus, another single-stranded RNA 
virus, also activates DCs through both TLR7 and TLR9 
(62). In addition, as demonstrated recently, certain metab-
olites such as the hemozoin of malaria parasites may signal 
through TLR9 (63). Thus, TLR9 may sense not only un-
methylated, CpG-rich DNA, but also other microbial or 
  viral components.
In addition to TLR7, TLR8 has also been shown to re-
spond to certain single-stranded RNA viruses such as HIV, 
human parechovirus 1, and Cocksackie virus B (34, 64, 65). 
To determine whether YF-17D also signals through TLR8, 
HEK293 cells stably transfected with human TLR8 and an 
NFκB-luciferase reporter were cultured with YF-17D or the 
synthetic TLR7/8 agonist 3M-003. Cell lysates were mea-
sured for luciferase activity as a measure of NFκB activation 
downstream of TLR8 (Fig. 3). After 1 d of culture, an 11-
fold increase in luciferase activity was measured from the cells 
treated with 3M-003, but there was only a modest increase in 
activity from YF. However, on the second day of culture (af-
ter the virus had a chance to begin replication), YF produced 
an 18-fold increase in luciferase activity. The very slight de-
crease in the response induced by 3M-003 is likely a refl  ec-
tion of the earlier eff  ect of the compound through the NFκB 
promoter and decay of the NFκB response, and not decay 
of the compound itself. The comparatively delayed response 
by the virus is more likely to be explained by the kinetics of 
Figure 5.  YF-17D induces effi  cient induction of antigen-specifi  c 
CD8+ T cells, and a mixed Th1/Th2 cytokine profi  le in vivo. Mice 
were injected with 2.5 × 106 OT-I TCR transgenic T cells and allowed to 
rest overnight. YF-Ova8 vaccinations were administered subcutaneously 
and the draining lymph nodes were collected 5 d later. A portion of cells 
was stained directly ex vivo for CD8 and Thy 1.2 to evaluate clonal expan-
sion of SIINFEKL-specifi  c CD8+ T cells by FACS (A). The remaining cells 
were placed into culture and restimulated with SIINFEKL or cultured in 
media alone. After 3 d, the induction of IFN-γ, IL-4, IL-5, and IL-13 cyto-
kines was measured by intracellular FACS staining (B, IFN-γ) or by ELISA 
(B and C). Error bars represent standard deviation. These data are repre-
sentative of three independent experiments.418  YF-17D ACTIVATES MULTIPLE TLRS TO STIMULATE POLYVALENT IMMUNITY | Querec et al.
  cellular infection and subsequent synthesis of viral compo-
nents required to stimulate the TLR8–NFκB pathway. Thus, 
YF-17D appears to activate DCs via multiple TLRs.
YF-17D induces DC activation and a mixed Th1/Th2 T cell 
response in vivo
Given that YF-17D activates multiple DC subsets via dis-
tinct TLRs, we sought to determine the quality of the adap-
tive immune responses stimulated by this vaccine. We fi  rst 
wanted to ascertain whether DCs were activated at all in 
vivo. YF-17D or control TLR ligands were injected sub-
cutaneously and, 1 d later, the draining lymph nodes were 
isolated and the phenotype and activation status of DCs was 
evaluated by fl  ow cytometry. The costimulatory molecules 
CD86 and CD40 in addition to the MHC class I molecule 
I-Ab were all clearly up-regulated when compared with the 
PBS injection at equivalent levels to that induced by LPS 
(Fig. 4), although we were unable to detect any substantial 
up-regulation of CD80.
It has been shown previously that most TLR ligands in-
duce robust Th1 responses (66, 67), but several studies sug-
gest that signaling via TLR 2 results in very weak induction 
of IL-12p70 in DCs and a bias toward the Th2 or T regula-
tory pathway (44–49, 68–71). Because YF-17D signaled 
through TLR2, 7, 8 and 9, it was important to characterize 
the quality of the T cell response after the DC activation 
in vivo. For this purpose, we obtained YF-Ova8, which 
  expresses a cytotoxic T lymphocyte epitope derived from 
chicken ovalbumin (SIINFEKL) (15). These recombinant vi-
ruses replicated comparably to the YF-17D vaccine strain in 
cell culture (unpublished data) and stably expressed the SIIN-
FEKL peptide, and infected cells presented the antigen in the 
context of MHC class I. YF-Ova8 was injected subcutane-
ously into Thy1.1+ mice that had received 2.5 × 106 OT-I 
transgenic T cells (Thy 1.2+) 1 d earlier; 5 d after vaccination, 
the cells in the draining lymph nodes were either analyzed 
directly by fl  ow cytometry or restimulated in vitro with SI-
INFEKL for T cell proliferation assays and cytokine analysis 
of cell culture supernatants. YF-Ova8 induced clonal expan-
sion of antigen-specifi  c CD8+ T cells, as indicated by the in-
creased frequency of CD8+ Thy 1.2+ cells (Fig. 5 A). 5 d 
after vaccination, the draining lymph nodes were isolated, 
and single cell suspensions were prepared and cultured in vitro 
with SIINFEKL peptide or in media. 72 h later, the in  duction 
of Th1 and Th2 cytokines, IFN-γ (Fig. 5 B) and IL-4, IL-5, 
IL-13, and IL-10 (Fig. 5 C), in culture was evaluated by 
ELISA and by intracellular fl  ow cytometry. As indicated in 
Fig. 5 B, YF-Ova8 induced the production of IFN-γ by 
CD8+ T cells. This cytokine production was largely specifi  c 
to the SIINFEKL peptide as indicated by much higher 
  frequency of CD8+IFN-γ+ cells in response to YF-Ova8 
relative to immunization with nonrecombinant YF-17D 
(Fig. 5 B). However, there were still nanograms/ml amounts 
produced (Fig. 5 B) by cells incubated with media alone (pre-
sumably as a result of viral carry over) and the ensuing T cell 
responses to endogenous YF-17D proteins. In contrast with 
Figure 6.  Induction of Th1 and Tc1 responses by YF-17D is depen-
dent on MyD88. Wild-type or MyD88−/− mice were vaccinated subcuta-
neously with YF-17D. Control mice were injected with supernatants from 
mock transfected SW-480 cells. 10 d later, the draining lymph nodes were 
harvested and single cell suspensions were cultured in vitro in media 
alone or with a combination of CD8+ T and CD4+ T cell epitopes from 
YF-17D as described in Materials and methods. 3 d later, the induction of 
IFN-γ was measured by ELISA (A) and by intracellular cytokine staining 
(B and C). These data are representative of three independent experiments 
with three mice per group in each experiment.
IFN-γ, the production of the Th2 cytokines IL-4, IL-5, IL-
13, and IL-10 did not   appear to be specifi  c to OVA, as re-
stimulation with  SIINFEKL did not increase their production. JEM VOL. 203, February 20, 2006  419
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This is likely a result of the fact that the OT-1 CD8+ trans-
genic T cells may have an intrinsic bias to secrete IFN-γ and 
their relatively high frequency in this adoptive transfer system 
would result in much higher levels of IFN-γ (but not IL-4, 
IL-5, or IL-13) being secreted. In contrast, the endogenous 
YF-17D proteins may stimulate specifi  c T cells that produce 
a mixed Th1/Th2 profi  le; thus, the bulk of the Th2 cyto-
kines detected in this system may well be produced by such 
T cells and, thus, be produced independently of SIINFEKL 
stimulation (Fig. 5 C).
Distinct TLRs differentially regulate the Th1/Th2 bias 
in response to YF-17D
We next sought to determine the contribution that individual 
TLRs made to the quality of the T cell response induced by 
YF-17D. Based on previous fi  ndings that MyD88−/− mice 
show a selective defect in Th1 responses (66), one possibility 
was that YF-17D signaling through TLRs only resulted in a 
Th1 response and that the Th2 responses were mediated by 
some other innate immune receptors. Alternatively, signal-
ing via TLR2 might mediate Th2 or T regulatory responses 
(44–49, 68–71). To distinguish between these possibilities, 
wild-type or MyD88−/− mice were injected subcutaneously 
with either YF-17D or with supernatant from mock-infected 
SW-480 cells. 5 or 10 d later, the draining lymph nodes were 
removed and single cell suspensions from these lymph nodes 
were cultured in vitro either in media alone or with a mixture 
of CD4+ T cell epitopes and CD8+ T cell epitopes that had 
been previously identifi  ed (72). The CD4+ T cell epitope is 
an I-Ab–restricted epitope from the viral envelope protein 
(residues 231–247 from the envelope protein, L  V  E  F  E  P  P  H  A-
A  T  I  R  V  L  ), whereas the CD8+ T cell epitopes are comprised 
of one subdominant H-2Db–restricted epitope (residues 1–15 
from the E1 envelope protein, A  H  C  I  G  I  T  D  R  D  F  I  E  G  V  ), and 
another H-2Kb–restricted dominant epitope mapped to the 
NS3 protein (residues 261–275 from the NS3 protein, V  I  D-
A  M  C  H  A  T  L  T  Y  R  M  L  ) (72). After 3 d, the supernatants were 
assayed for cytokines (IFN-γ, IL-4, IL-5) and intracellular 
staining of CD8+, CD4+, and IFN-γ on the cells was per-
formed. As shown in Fig. 6 A, in wild-type mice, YF-17D 
induced high levels of IFN-γ. This induction occurred even 
when the cells were cultured in media alone, likely refl  ecting 
carry over of viral components that served as antigen for in 
vitro restimulation. In MyD88−/− mice, however, there was 
a profound reduction in IFN-γ levels (Fig. 6 A). These trends 
were refl  ected in the intracellular staining assays for IFN-γ+ 
cells shown in Fig. 6 B. Similar trends were also observed 
with CD4+IFN-γ+ cells (Fig. 6 C). Thus, as described previ-
ously (66), MyD88 appears to be critical for the induction of 
Th1 and Tc1 responses. Also, in agreement with previous 
fi  ndings, MyD88−/− mice displayed enhanced induction of 
IL-4 and IL-5 (unpublished data).
Figure 7.  TLR2 exerts an inhibitory effect on Th1 and Tc1 re-
sponses against YF-17D. Wild-type or TLR2−/− mice were vaccinated 
subcutaneously with YF-17D. Control mice were injected with superna-
tants from mock transfected SW-480 cells. 5 or 10 d later, the draining 
lymph nodes were harvested and single cell suspensions cultured in 
vitro in media alone, or with a combination of CD8+ T and CD4+ T cell 
epitopes from YF-17D. 3 d later, the induction of IFN-γ was measured 
by intracellular cytokine staining (A and B). These data are representa-
tive of four independent experiments with three mice per group in 
each experiment. 420  YF-17D ACTIVATES MULTIPLE TLRS TO STIMULATE POLYVALENT IMMUNITY | Querec et al.
Next, we evaluated immune responses in TLR2−/− mice. 
The experiments were performed exactly as described in the 
previous paragraph with MyD88−/− mice. In brief, we im-
munized wild-type or TLR2−/− mice subcutaneously with 
either YF-17D or with supernatant from mock-infected SW-
480 cells. 5 or 10 d later, the draining lymph nodes were re-
moved, and single cell suspensions from these lymph nodes 
were cultured in vitro, either in media alone or with a mix-
ture of CD4+ T cell epitopes and CD8+ T cell epitopes, 
which had been previously identifi  ed as described in the pre-
vious paragraph (72). After 3 d, the supernatants were assayed 
for cytokines (IFN-γ, IL-4, IL-5) and intracellular staining of 
CD8+, CD4+, and IFN-γ on the cells was performed. As 
shown in Fig. 7 A, the frequency of CD8+IFN-γ+ T cells in 
wild-type mice at day 10 is 1.05%. However, at this time 
point, the TLR2−/− mice contained 3.63%. A similar trend was 
observed at day 5. Furthermore, in the case of CD4+IFN-γ+ 
T cells (Fig. 7 B), at day 5 after immunization, the response in 
TLR2−/− mice appeared to be markedly higher than in wild-
type mice. However, by day 10, the CD4+IFN-γ+ response 
appeared to have subsided, and no diff  erences were apparent. 
This suggests that signaling through TLR 2 may exert an in-
hibitory eff  ect on the induction of CD4+IFN-γ+ or CD8+ 
IFN-γ+ cells in response to YF-17D. These results are con-
sistent with the enhanced secretion of IFN-γ in TLR2 
knockout splenocytes, relative to wild-type splenocytes as 
evaluated by ELISA (Fig. S4, available at http://www.jem.
org/cgi/content/full/jem.20051720/DC1). These results are 
consistent with previous fi  ndings that TLR2 signaling in-
duces Th2 or T regulatory responses (26, 44–49, 68–71). In-
terestingly, in the case of the Th2 cytokines IL-4 and IL-5, 
there appeared to be a modest decrease in TLR 2−/− mice 
(unpublished data). Collectively, these data suggest that 
TLR2 might regulate the induction of Th1/Th2 balance in 
response to YF-17D.
D  I  S  C  U  S  S  I  O  N 
The data presented here, together with that reported recently 
by Barba-Spaeth et al. (50), off  er some insights into the mech-
anism of action of YF-17D, one of the most eff  ective vaccines 
available. In particular, our data suggest that YF-17D activates 
DCs via multiple TLRs, including TLR2, 7, 8 and 9, and 
that signaling via distinct TLRs exerts diff  erential eff  ects on 
the quality of the antigen-specifi  c T cell response induced by 
YF-17D. Whether other TLRs, particularly TLR3, which is 
a receptor for double-stranded RNA (36), are also involved in 
YF-17D recognition is at present unclear.
The biological signifi  cance of activation of several TLRs 
is highlighted by two intriguing aspects of the data. First, the 
absence of a single TLR appears to result in a signifi  cant im-
pairment of IL-12p40 and IL-6 (Fig. 2). This is surprising 
because it might have been expected that other TLRs would 
compensate for this defi  ciency. One explanation for this ob-
servation is that the TLRs signal in a synergistic manner, and 
that YF-17D contains suboptimal amounts of individual TLR 
ligands, which by themselves stimulate suboptimal responses, 
but which can signal in concert, to produce a synergistic 
  eff  ect. This hypothesis is consistent with two recent reports 
that suggest that selected TLR combinations can indeed syn-
ergistically trigger a Th1 polarizing program in human DCs 
(73, 74). In the case of YF-17D, whether such synergy might 
occur by triggering multiple TLRs on a single DC subset, 
by triggering multiple TLRs on distinct DC subsets, or by 
both mechanisms is yet to be determined. A second intrigu-
ing aspect to the data is that signaling via distinct TLRs appear 
to diff  erentially bias the Th1/Th2 balance. Thus, eliminating 
signaling via MyD88 impairs Th1 responses, whereas eliminat-
ing TLR2 signaling enhances Th1 responses (Figs. 5 and 6). 
This is consistent with emerging data that distinct TLRs may 
diff  erentially  aff   ect the Th1/Th2 balance (44–49, 68–71). 
Therefore, vaccines that target multiple TLRs might facilitate 
both immune synergy as well as polyvalent immune responses 
to generate broad-based protective immunity. In this context, 
a recent study suggests that conjugating HIV Gag protein to 
a TLR7/8 agonist results in activation of both myeloid and 
pDCs, and enhances the magnitude and quality of Th1 and 
CD8+ T cell responses in nonhuman primates (75).
The question of which types of immune responses of-
fer protection against challenge with the pathogenic strain 
of yellow fever virus is of considerable interest. This was not 
addressed in the present study, primarily because yellow fever 
appears to be rather host (primate) restricted and mice are 
not very susceptible. Even immunosuppressed mice appear 
to be relatively poor hosts. In fact, several investigators ap-
pear to have used nonhuman primates for their experiments 
with yellow fever and chimeric yellow fever viruses (6–15). 
However, it is known that YF-17D does kill mice after in-
tracerebral challenge (9), but the relevance of such a model 
to yellow fever infection in humans is questionable. These 
issues notwithstanding, one might speculate on which types 
of responses confer protection against yellow fever. Though 
neutralizing antibody titers are thought to be important, a 
role for cytotoxic T cell responses has also been suggested 
(5). However, what infl  uence the Th1/Th2 balance might 
have on protection is unknown. Because Th1 versus Th2 cy-
tokines are thought to favor the development of cytotoxic T 
cells versus antibodies, respectively, it is conceivable that both 
Th1 and Th2 responses are important for protection. Thus, 
intracerebral infection of MyD88 knockout mice or TLR2 
knockout mice might have both resulted in impaired survival 
of the hosts as a result of perturbed Th1/Th2 balances.
Finally, it is also important to address the question of pre-
cisely which viral components act through which innate im-
mune receptors. In this context, it is important to note that 
live viral vaccines contain not only viral proteins and nucleic 
acids, but also cellular contaminants derived from the cell 
lines in which the vaccines were grown. Such cellular con-
taminants (Janeway’s “dirty little secrets” [reference 76] or 
Matzinger’s “danger signals” [reference 77]), may well play 
important roles in the induction and modulation of vaccine 
induced immune responses. Thus, the chicken embryos and 
cell lines in which YF-17D are grown are potential sources of JEM VOL. 203, February 20, 2006  421
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these dirty little secrets or danger signals. In this context, 
avian retroviral proteins, ovalbumin, and chicken DNA are 
all found in YF-17D preparations for human use (78). It is 
thus likely that these factors and other nonviral components 
of the YF-17D vaccine, such as heat shock proteins and uric 
acid, contribute to the induction of an immune response. 
Both heat shock proteins and uric acid are released from 
stressed cells and are potent activators of DCs and monocytes 
(for review see reference 79). Thus, future vaccinologists 
should not only concern themselves with using the right 
combination of adjuvants but also having vaccine prepara-
tions that are “clean,” but which recapitulate the immuno-
genicity of the “dirty” vaccines. Furthermore, whatever the 
source of the molecules that stimulate a given TLR or PRR, 
clearly further work is required to determine the specifi  c 
combinations of PRRs (the correct “code” of innate im-
mune buttons) that promote a particular facet of the immune 
response, such Th1/Th2 balance, neutralizing antibody re-
sponses, long-lived antibody-producing cells that home to 
mucosal tissues and continuously secrete high-affi   nity neu-
tralizing antibody, and long-lived memory T cells.
In conclusion, the present data enhance our understand-
ing of the molecular mechanisms of action of YF-17D and 
highlight the potential of vaccination strategies that use com-
binations of diff  erent TLR ligands to stimulate polyvalent 
and synergistic immune responses. The present approach of 
determining the TLRs that YF-17D signals through could be 
used to deconstruct the immunological basis for the effi   cacy 
of other successful vaccines. It is likely that many of these 
vaccines, which consist of live attenuated viruses or bacteria, 
may well signal through multiple TLRs, as well as other non-
TLRs such as RIG-1 (62). Conversely, it conceivable that 
“poor” vaccines, which require repetitive boosts to generate 
robust protective responses, do not trigger TLRs at all or 
even inhibit TLR signaling. A common method used in the 
construction of many developing vaccines is to use a single 
adjuvant, such as CpG DNA, in combination with an anti-
gen. However, such vaccines maybe limited in the quantity 
and quality of the immune response generated and, therefore, 
may not provide the most eff  ective prevention or treatment 
possible. Thus, future vaccine strategies aimed at incorporat-
ing multiple TLR ligands and antigens into delivery systems 
such as nanoparticles, which can target specifi  c DC subsets in 
vivo, is likely to be of great benefi  t in conferring the degree 
of immunogenicity and protection mediated by our best vac-
cines such as the yellow fever vaccine YF-17D.
MATERIALS AND METHODS
Mice. Mutant mice (MyD88−/−, TIRAP−/−, TLR2−/−, TLR4−/−, TLR7−/−) 
were provided by S. Akira (Osaka University, Osaka, Japan) and were either 
in the C57BL/6 background or in a mixed C57BL/6 × 129 background 
(backcrossed at least fi  ve times to C57BL/6). C3H/HeJ and C3H/HeN 
were purchased from The Jackson Laboratory and Taconic Farms, respec-
tively. Spleens from TLR 9−/− mice on the mixed C57BL/6 × 129 
  background were provided by R. Medzhitov (Yale University School of 
Medicine, New Haven, CT). In each case, the appropriate littermate control 
was used. All mutant mice and controls were sex- and age-matched and 
  between 6 and 16 wk old. For adoptive transfer studies, OT-1 TCR trans-
genic mice and B6.PL mice were purchased from The Jackson Laboratory 
and bred at the Yerkes Vivarium. B6.PL recipients were injected i.v. with 
2.5 × 106 OT-1 TCR transgenic T cells. All animal studies were approved 
by the Institutional Animal Care and Use Committee of Emory University.
Virus. YF-17D subpassaged from YF-VAX (Aventis Pasteur) in SW-480 
cells was a gift from R. Ahmed (Emory University, Atlanta, GA), and 
YF-Ova8 (encoding the SIINFEKL peptide) and YF-FL were gifts from 
R. Andino (University of California, San Francisco, CA) (15). Viruses were 
passaged in SW-480 cells in DMEM + 10% FBS + penicillin/streptomycin. 
Cell culture supernatants were collected  6 d after infection when  20% 
cytopathic eff  ect was noted. Supernatants were clarifi  ed by centrifugation 
twice at 750 g for a total of 20 min. This crude virus stock was purifi  ed fur-
ther, as follows: sucrose purifi  ed virus was generated by centrifuging the vi-
rus through a PBS + 35% sucrose + 10 μM Tris cushion at 100,000 g for 
2 h. The viral pellet was resuspended in PBS and frozen at −80°C in ali-
quots. Viral titers were calculated by plaque assay using Vero cells. Virus was 
inactivated by either incubating at 56°C for 1 h or UV irradiated with 120 
mJ/cm2 for 5 min.
Stimuli. Purifi  ed E. coli was a gift from T. van Dyke (Boston University, 
Boston, MA). CpG A (ODN 2336) and CpG B (ODN 2006) DNA was 
purchased from Coley Pharmaceutical. Pam-3-cys was obtained from EMC 
Microcollections. 3M-003, a proprietary TLR7/8 agonist was a gift from 
K. Gorden (3M Corporation, St. Paul, MN).
Purifi  cation of mouse splenic CD11c+ DCs. CD11c+ DCs were puri-
fi  ed from the spleens of Flt-3L–injected mice. Mice were injected with 20 μg 
Flt-3L per day for nine consecutive days. On the 10th day, spleens were di-
gested with Collagenase, Type IV (1 mg/ml; Worthington Biochemical) in 
complete DMEM + 2% FBS for 30 min at 37°C. Cells were washed 2× 
with PBS + EDTA + FBS and cell cultures of >95% CD11c+ DC purity 
were established after enrichment of splenocytes with CD11c+ microbeads 
(Miltenyi Biotec).
Human DCs. Human mDCs were generated from apheresis samples of 
healthy donors. PBMCs were plated at 10 × 106 cells/well in six-well plates. 
After 2 h, nonadherent cells were removed and the adherent monocytes 
were cultured in RPMI 1640 + 10% FBS + 50 μg/ml GM-CSF + 10 μg/
ml IL-4 (PeproTech) for 6 d. After this time, the nonadherent DCs were 
collected, washed, and used for experiments. Human pDCs were enriched 
from PBMCs using BDCA-2 microbeads (Miltenyi Biotec).
In vitro cultures. The mDCs, pDCs, and mouse CD11c+ DCs were plated 
at 106 cells/ml in 48-well culture dishes and incubated with the stimuli un-
der humid conditions at 5% CO2 and 37°C. The human DCs were cultured 
in RPMI 1640 + 10% FBS + pen/strep. Human IL-3 (PeproTech) was 
added for the pDCs. Mouse DCs were cultured in complete DMEM + 10% 
FBS. Costimulatory molecule expression was analyzed by fl  ow cytometry 
after 48 h for human DCs. Alternatively, the supernatants were analyzed af-
ter 48 h for cytokines.
Staining for YF-17D in DCs. Cells were washed in staining medium and 
stained for surface CD86 for 30 min, 0°C. Subsequently cells were washed 
twice then fi  xed and permeabilized using a BD Biosciences cytofi  x/perm re-
agent kit following the manufacturer’s instructions. A rabbit polyclonal anti-
sera that recognizes the nonstructural proteins NS4A and NS4B (C. Rice, 
The Rockefeller University, New York, NY) was used to detect intracellular 
virus (30 min, 0°C). Next, the cells were washed twice to remove unbound 
antibody and stained with allophycocyanin-labeled anti–rabbit secondary an-
tibody for an additional 30 min at 0°C followed by washing. Data was 
  acquired on FACSCalibur and analyzed using  Flowjo analysis software.
Injections. C57BL/6 mice were injected subcutaneous with either PBS 
alone, 50 μg Pam-3-cys, 25 μg E. coli LPS, 50 μg CpG B, 2 μg 3M-003, or 422  YF-17D ACTIVATES MULTIPLE TLRS TO STIMULATE POLYVALENT IMMUNITY | Querec et al.
106 PFU YF-17D. After 1 d, the draining popliteal and inguinal lymph 
nodes were dissected and the DCs were isolated with collagenase, type IV 
digestion. The cells were stained and analyzed by fl  ow cytometry for co-
stimulatory molecule expression. B6.PL (Thy 1.1+) mice reconstituted with 
OT-1 TCR transgenic T cells (Thy 1.2+) were injected subcutaneously 
with 50 μg of MHC class I–restricted OVA peptide (SIINFEKL; OVA257-
264; BioSynthesis) with 25 μg E. coli LPS or 106 PFU of YF-FL or YF-
Ova8. After 4 d, the cells from the draining popliteal and inguinal lymph 
nodes were subjected to assays as described in the T cell assays section. 
Evaluation of infection of DCs. Infection assays were performed as de-
scribed previously by Barba-Spaeth et al. (50). In brief, DCs were washed in 
RPMI 1640 and cultured with YF-17D for 1 h at 37°C. The infection was 
quenched with 5% pooled human serum and the cells were washed exten-
sively to remove excess virus. After 1 h of infection, DCs were resuspended 
in conditioned media and incubated for 24 h before monitoring for infection. 
Surface staining was done in serum containing media at 4°C. Antibodies 
were obtained from BD Biosciences. Cytoperm/CytoFix Kit (BD Biosci-
ences) was used for fi  xation and permeabilization. C12 is a rabbit polyclonal 
antisera that recognizes the nonstructural proteins NS4A and NS4B, and 
was a gift from C. Rice (50). Secondary antibodies used were PE (Jackson 
ImmunoResearch Laboratories) or allophycocyanin (Invitrogen).
T cell assays. Isolated lymph node cells from injected mice were either 
stained directly ex vivo and analyzed by fl  ow cytometry for T cell clonal ex-
pansion, or restimulated in vitro. Cells were plated at 5 × 105 cells/well in 
96-well plates and cultured in complete DMEM + 10% FBS alone or with 
various concentrations of MHC class I–restricted OVA SIINFEKL peptide, 
or an I-Ab–restricted epitope from the viral envelope protein (residues 
231–247 from the envelope protein, L  V  E  F  E  P  P  H  A  A  T  I  R  V  L  ), or an H-2Db–
  restricted epitope (residues 1–15 from the E1 envelope protein, A  H  C  I  G  I  T-
D  R  D  F  I  E  G  V  ), or an H-2Kb–restricted dominant epitope mapped to the 
NS3 protein (residues 261–275 from the NS3 protein, V  I  D  A  M  C  H  A  T  L  T  Y-
R  M  L  ) (72), or a combination of these epitopes. On the third day, the wells 
for in vitro proliferation assays had 1 μCi of [3H]thymidine added to them. 
On the fourth day, supernatants were collected for cytokine measurement, 
or the cultures were frozen at −20°C to lyse the cells for the measurement 
of thymidine incorporation.
Cytokine measurement. For the mouse cytokines, the following kits were 
used: IL-4 and IFN-γ were obtained from eBioscience; IL-5, IL-6, IL-10, 
and IL-12p40 were obtained from BD Biosciences; and IL-13 was obtained 
from R&D Systems. Human IL-6, TNF-α, IL-10, IP-10, and MCP-1 were 
all measured using kits obtained from BD Bioscience. IFN-α was measured 
with the kit obtained from Biosource.
Transfection experiments. The HEK293 cells stably transfected with hu-
man TLR8 and an NFκB driven luciferase reporter were a gift from 3M 
Pharmaceuticals. Cells were plated at 4 × 104 cells per well in 96-well plates 
with DMEM + 10% FBS + pen/strep in the evening. 18 h later, the cells 
were stimulated with 10 μM of 3M-003, 4 × 103 PFU of YF-17D, or left 
in media alone. After 24 or 48 h of stimulation, the luciferase activity of the 
cells was assayed using the Luciferase Assay System (Promega).
Online supplemental material. YF-17D induces IL-12p40 and IL-12p70 
in both human mDCs (Fig. S1, A and B) and murine splenic CD11c+ DCs 
(Fig. S1 C). In Fig. S2, YF-17D productively infects human mDCs. Imma-
ture human mDCs were exposed to YF-17D, and 48 h later the DCs were 
harvested stained for intracellular fl   ow cytometric analysis of NS4A and 
NS4B. Fig. S3 shows that cellular DNA does not contribute to the immune 
stimulatory eff  ects of YF-17D. Fig. S4 depicts TLR2 exerting an inhibitory 
eff  ect on Th1 responses induced by IFN-γ. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20051720/DC1.
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